Drug Type Small molecule drug |
Synonyms (8β)-10-methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyridinecarboxylate (ester), 10-methoxy-1,6-dimethylergoline-8β-methanol 5-bromonicotinate, Nicergo1ine + [10] |
Target |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (16 Dec 1978), |
Regulation- |
Molecular FormulaC24H26BrN3O3 |
InChIKeyYSEXMKHXIOCEJA-FVFQAYNVSA-N |
CAS Registry27848-84-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01290 | Nicergoline |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dizziness | CN | 15 Dec 2000 | |
Intellectual Disability | CN | 15 Dec 2000 | |
Mood Disorders | CN | 17 Sep 1999 | |
Peripheral Vascular Diseases | CN | 17 Sep 1999 | |
Arteriosclerosis | KR | 16 Dec 1978 | |
Brain Infarction | KR | 16 Dec 1978 | |
Dementia | KR | 16 Dec 1978 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | US | - | |
Affective Disorders, Psychotic | Phase 1 | CN | 30 Apr 2020 | |
Dementia, Vascular | Phase 1 | CN | 30 Apr 2020 |
Not Applicable | 8 | dxiilrnilh(hpcpcieemt) = xlvymtetyz vctjcqzzca (ewlmqcsuig ) | - | 23 Apr 2023 | |||
(Autologous Serum) | dxiilrnilh(hpcpcieemt) = idydwvkizk vctjcqzzca (ewlmqcsuig ) | ||||||
Not Applicable | 9 | cdxkfjijai(mxezpcngxf) = eyfhggvacz rdpqsebkcb (vyjnrdjrlt ) | - | 07 May 2017 |